97 related articles for article (PubMed ID: 22239178)
1. Novel targeted therapies in head and neck cancer.
Ferreira MB; Lima JP; Cohen EE
Expert Opin Investig Drugs; 2012 Mar; 21(3):281-95. PubMed ID: 22239178
[TBL] [Abstract][Full Text] [Related]
2. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
3. New advances in targeted therapies for squamous cell carcinoma of the head and neck.
Machiels JP; Schmitz S
Anticancer Drugs; 2011 Aug; 22(7):626-33. PubMed ID: 21048493
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for squamous-cell carcinoma of the head and neck.
Papaspyrou G; Werner JA; Dietz A
Expert Opin Pharmacother; 2011 Feb; 12(3):397-409. PubMed ID: 21254947
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway.
Lau PC; Chan AT
Anticancer Drugs; 2011 Aug; 22(7):665-73. PubMed ID: 21709616
[TBL] [Abstract][Full Text] [Related]
7. Emerging molecular targeted therapies in the treatment of head and neck cancer.
Bozec A; Peyrade F; Fischel JL; Milano G
Expert Opin Emerg Drugs; 2009 Jun; 14(2):299-310. PubMed ID: 19519286
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy in head and neck cancer.
Kundu SK; Nestor M
Tumour Biol; 2012 Jun; 33(3):707-21. PubMed ID: 22373581
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents.
Harrington KJ; Kazi R; Bhide SA; Newbold K; Nutting CM
Indian J Cancer; 2010; 47(3):248-59. PubMed ID: 20587899
[TBL] [Abstract][Full Text] [Related]
10. [Anti-angiogenesis - a therapy concept in the treatment of head and neck carcinomas? A review].
Riedel F; Hörmann K
Laryngorhinootologie; 2001 Sep; 80(9):535-41. PubMed ID: 11555787
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
Cooper JB; Cohen EE
Head Neck; 2009 Aug; 31(8):1086-94. PubMed ID: 19378324
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeted therapy of head and neck cancer: review and clinical development challenges.
Le Tourneau C; Faivre S; Siu LL
Eur J Cancer; 2007 Nov; 43(17):2457-66. PubMed ID: 17904355
[TBL] [Abstract][Full Text] [Related]
13. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Cohen EE
J Clin Oncol; 2006 Jun; 24(17):2659-65. PubMed ID: 16763280
[TBL] [Abstract][Full Text] [Related]
14. Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
Gilbert J; Argiris A
Clin Adv Hematol Oncol; 2006 Aug; 4(8):611-9. PubMed ID: 17099619
[TBL] [Abstract][Full Text] [Related]
15. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
[TBL] [Abstract][Full Text] [Related]
16. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
17. Molecular-targeted therapies in head and neck cancer.
Rao SD; Fury MG; Pfister DG
Semin Radiat Oncol; 2012 Jul; 22(3):207-13. PubMed ID: 22687945
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.
Timpson P; Wilson AS; Lehrbach GM; Sutherland RL; Musgrove EA; Daly RJ
Cancer Res; 2007 Oct; 67(19):9304-14. PubMed ID: 17909038
[TBL] [Abstract][Full Text] [Related]
20. [Use of docetaxel in treatment of squamous-cell carcinoma of head and neck].
Subramanian S; Kanagavel D; Petenko NN; Orlova KV; Samoĭlenko IV; Demidov LV
Vopr Onkol; 2011; 57(4):421-6. PubMed ID: 22191228
[No Abstract] [Full Text] [Related]
[Next] [New Search]
